CEP104

Across TCGA pan-cancer cohorts, CEP104 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CEP104 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CEP104 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP104 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

KIRP, LUSC, and MESO are the cancer types where CEP104 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.618	0.934	<.001	36	view →
LUSC	DFS	Median	All	0.161	0.646	.004	20	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
HNSC	DFS	Median	II,III,IV	0.178	0.612	.040	9	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	9	view →
STAD	OS	Median	IV	0.805	0.283	.031	7	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CEP104–KIRP (OS)

Open the KIRP breakdown →